Literature DB >> 28424916

Bilateral pallidotomy for Meige syndrome.

Krasimir Minkin1, Kaloyan Gabrovski2, Petia Dimova2, Rossitsa Tanova2, Marin Penkov3, Yuri Todorov3, Kiril Romansky3.   

Abstract

Meige syndrome (MS) is usually described as a combination of blepharospasm with oromandibular dystonia. There are a large number of case reports of deep brain stimulation (DBS) of the globus pallidus internus (GPI) for MS and only one report of unilateral pallidotomy (PT). We report the first case of staged bilateral PT for treatment of a patient with MS using intraoperative high-frequency stimulation in order to predict and prevent postoperative deficit. There was a significant improvement of the Burk-Fahn-Marsden dystonia rating scale from 26 to 3. There were no adverse postoperative neurological and neuropsychological events.

Entities:  

Keywords:  Deep brain stimulation; Dystonia; High frequency stimulation; Meige syndrome; Pallidotomy; Radiofrequency lesions

Mesh:

Year:  2017        PMID: 28424916     DOI: 10.1007/s00701-017-3178-0

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  4 in total

Review 1.  Recent advances in understanding and managing dystonia.

Authors:  Stephen Tisch
Journal:  F1000Res       Date:  2018-07-24

2.  Pallidal versus subthalamic deep-brain stimulation for meige syndrome: a retrospective study.

Authors:  Jiayu Liu; Hu Ding; Ke Xu; Ruen Liu; Dongliang Wang; Jia Ouyang; Zhi Liu; Zeyu Miao
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

3.  Safety and efficacy of unilateral and bilateral pallidotomy for primary dystonia.

Authors:  Shiro Horisawa; Atsushi Fukui; Nobuhiko Takeda; Takakazu Kawamata; Takaomi Taira
Journal:  Ann Clin Transl Neurol       Date:  2021-03-15       Impact factor: 4.511

Review 4.  Bilateral Pallidotomy for Dystonia: A Systematic Review.

Authors:  Liesanne M Centen; D L Marinus Oterdoom; Marina A J Tijssen; Ivon Lesman-Leegte; Martje E van Egmond; J Marc C van Dijk
Journal:  Mov Disord       Date:  2020-11-20       Impact factor: 10.338

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.